Drug Profile
ENERGI F703
Alternative Names: ENERGIF703Latest Information Update: 10 Jul 2023
Price :
$50
*
At a glance
- Originator Energenesis Biomedical
- Class Foot disorder therapies; Skin disorder therapies
- Mechanism of Action AMP activated protein kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Diabetic foot ulcer
- Phase II Varicose ulcer
Most Recent Events
- 30 May 2023 Phase-III clinical trials in Diabetic foot ulcer in USA (Topical) (NCT05930210)
- 26 Jul 2022 Phase-II clinical trials in Varicose ulcer (In adults, In the elderly) in Taiwan (Topical) (NCT04078555)
- 25 Jun 2021 Efficacy and adverse events data from a phase II trial in Diabetic foot ulcer presented at the 81st Annual Scientific Sessions of the American Diabetes Association (ADA-2021)